Join Our E-mail Service

Receive Forum email updates
summitplenary

The Forum has Moved

HIV Forum joins University of California, Berkeley School of Public Health
Two leading institutions in public health and health policy are joining forces to accelerate the nation's progress in fighting HIV/AIDS, hepatitis C and tuberculosis in Washington - the Forum for Collaborative HIV Research and the University of California, Berkeley, School of Public Health. Click here to read the full press release. 

UPDATE Please click here for our new contact information

Updates on Routine HIV Testing in the U.S.

Keep up-to-date with the LATEST news and publications on routine HIV testing in the United States since the 2008 National Summit on HIV Diagnosis, Prevention, and Access to Care. 

Click here to read more.

Announcements

Follow the HIV Forum on
twitter-logo

Current Projects
Home
Review of Cardiovascular Disease in HIV Treatment

HIV disease and its therapies are associated with increased risk for cardiovascular (CV) disease. Teasing out the risk attributable to HIV itself vs. the risk potentially attributable to specific antiretrovirals is a difficult task. A better understanding of the increased risk and its etiology is important for clinical management, treatment guideline generation and regulatory policies.

Read more...
Global Surveillance of Antiretroviral Drug Safety

Considerable progress has been made in providing global access to antiretroviral therapy.  However, the effectiveness of treatment programs risks being compromised by problems related to toxicity, intolerance, drug-drug interactions, diversion, counterfeiting, inappropriate drug utilization and other issues.  These are examples of common phenomena affecting individual patients and public health, but not identified before clinical use and scarcely systematically reported in countries with limited infrastructures for monitoring of drug use and safety.

Read more...
Municipal Scale-up of HIV Testing in the United States
In 2006, CDC released recommendations for HIV testing recommending that HIV screening be a part of routine clinical care in all health-care settings for persons aged 13-64 years and all pregnant women.  Several cities across the U.S. have begun municipal-wide HIV testing scale-up programs intended to increase the numbers of persons tested for HIV, increase the number of persons aware of their HIV status, and to link to care persons infected with HIV.  Municipal scale-ups are underway in cities across the country including Oakland, Miami, Washington, DC, New York City, Houston, and Los Angeles.
Read more...
Standardization & Clinical Relevance of HIV Drug Resistance Testing: Availability of RESIST Data
The Forum in collaboration with Boehringer Ingelheim is making available the RESIST datasets from the pivotal tipranavir trials.
Read more...
HCV Drug Resistance Slide Set
Recognizing the need for education regarding HCV drug resistance, the Forum for Collaborative HIV Research's HCV Drug Development Advisory Group (academicians, clinicians, researchers and patient advocates) have contributed to a slide deck explaining resistance in HCV, its consequences as well as its mitigation.
Read more...
2010 HIV Summit
logoThe 2010 National Summit on HIV Diagnosis, Prevention, and Access to Care will take place November 17-19, 2010, National Harbor, MD.
Read more...
HIV Diagnostic and Monitoring Technologies in Resource Limited Settings

An update meeting to the Pediatric Diagnostic and Monitoring Technologies Meeting in 2006 as well as adult treatment and monitoring technologies was held in a roundtable format.

Read more...
HEP DART 2009, Frontiers in Drug Development for Viral Hepatitis Education Round-Table
An education roundtable will be at held the upcoming HEP DART meeting in Hawaii On Tuesday, December 8, 2009  to educate Hepatitis C virus infected patients and update physicians who treat them about risk for, and avoidance of drug resistance to the next generation of HCV antiviral therapies.
Read more...
IV. HCV Drug Resistance Advisory Group, November 2009
The Fourth HCV Drug Resistance Advisory Group (HCV DRAG) meeting was held to discuss HCV drug resistance issues for directly acting antivirals in clinical trials. 
Read more...
Consultation on the Inclusion of Adolescents in HIV Biomedical Prevention Clinical Trials
In collaboration with Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Allergy and Infectious Diseases, and the Office of AIDS Research. This consultation will focus on examining and discussing the desirability and timing of as well as barriers to enrollment of adolescents in these trials.  Participants will include representatives from academia, industry, HIV-affected communities, and various branches of the United States government.  These participants will offer an expanse of expertise covering the medical, behavioral, ethical, legal and regulatory ramifications of including or not including adolescents in biomedical prevention trials.
Read more...
<< Start < Prev 1 2 Next > End >>

Results 1 - 10 of 19